Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Praluzatamab Ravtansine (CX-2009) in Metastatic HR-Positive/HER2 Non-amplified Breast Cancer (mHR+/HER2− BC) and CX-2009 as Monotherapy and in Combination with Pacmilimab in Metastatic Triple-Negative Breast Cancer (mTNBC)

Kathy D. Miller¹, Leisha A. Emens², Sara M. Tolaney³, Sara A. Hurvitz⁴, Erika Hamilton⁵, Virginia Paton⁶, Alison Hannah⁶, Valentina Boni⁷

¹Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA; ²University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA; ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ⁴University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; ⁵Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; ⁶CytoMx Therapeutics, Inc., South San Francisco, CA, USA; ⁷START Madrid CIOCC, Comprehensive Cancer Center Clara Campal, HM Universitary Hospital Sanchinarro, Madrid, Spain
• Probody drug conjugates are a new class of conditionally activated antibody-drug conjugates consisting of 4 molecular components: the antibody; a peptide masking the antigen-binding site of the antibody; a protease cleavable linker designed to keep the peptide mask in place; and a toxin conjugated to the antibody (Figure 1)\(^1\)
• Upregulated tumor protease activity, a hallmark of cancer, cleaves the substrate linker and releases the masking peptide, which allows the antibody to bind to its target\textsuperscript{2}

• CX-2009 is a Probody drug conjugate that consists of a humanized anti-CD166 monoclonal antibody conjugated to DM4, a potent microtubule inhibitor known to be active against multiple cancer types (Figure 1)
  
  – CD166 (activated leukocyte cell adhesion molecule) is a transmembrane protein that functions as a junctional adhesion molecule and facilitates cell migration, differentiation, and hematopoiesis. It is widely expressed on dividing, normal, and malignant cells (Figure 2)\textsuperscript{3}
  
  – The incidence of high CD166 expression is >80\% for ER+/HER2–breast cancer and ~50\% for triple-negative breast cancer (TNBC) (Figure 2)
  
  – As designed, CX-2009 should primarily restrict target engagement to tumors that express CD166. Off-tumor/on-target toxicity to healthy tissue should be reduced; non-specific payload toxicity should be similar to that of other DM4 antibody-drug conjugates (ADCs)
BACKGROUND

Figure 2. CD166 expression among different tumor types.

GBM, glioblastoma; HNSCC, squamous cell carcinoma of the head and neck; NET, neuroendocrine tumor; TNBC, triple-negative breast cancer.

Summary

- Probody technology enables administration of an ADC against a previously undruggable ADC target at tolerable doses with signs of clinical benefit.
Rationale to Combine with Immune Checkpoint Inhibitors

- Cytotoxic payloads not only have cytotoxic effects but may also potentiate an immune response through multiples modalities
  - Cytotoxic payload/ADCs have been shown to induce immunogenic cell death in vitro and in vivo\(^4\)
- The activity of CX-2009 in combination with a Probody Checkpoint Inhibitor (CPI) therapeutic to mouse PD-1 was investigated in a subcutaneous mouse cell line cancer model\(^5\)
  - Neither CX-2009 nor anti-PD-1 Probody therapeutic monotherapy result in regressions in mice with established CT26-hCD166 tumors
  - The combination produced tumor regressions in 51% of mice
CTMX-M-2009-001 Study

- Dose escalation/dose-expansion trial (n=99)
- 27 sites in the US, Spain, Netherlands, and UK
- Advanced, pretreated solid tumors with disease progression after standard treatments
- Available tumor tissue for CD166 IHC analysis
- Prior maytansinoid treatment and neuropathy > Grade 1 exclusionary
- Evaluated two schedules
  - Q3W: 0.25 mg/kg, 10 mg/kg (n=89)
  - Q2W: 4 mg/kg, 6 mg/kg (n=10)
Summary of CX-2009 Phase 1 Data

Clinical Activity
- Tumor volume regression observed at CX-2009 doses ≥4 mg/kg IV Q3W
- Confirmed partial responses and clinically meaningful disease control, as measured by CBR16 (41%) and CBR24 (28%) was observed in patients with breast cancer

Clinical Safety
- Adverse events at the recommended phase 2 dose of 7 mg/kg Q3W are manageable
  - Ocular toxicity is dose related with higher incidence at doses ≥8 mg/kg Q3W
  - Most events recover/resolve within 2-3 weeks with either treatment interruption or ocular medications
- Based on activity and tolerability, the RP2D is 7 mg/kg Q3W

Translational Findings
- CX-2009 is activated/unmasked in tumors and is predominantly intact/masked in circulation
- Correlations between activated CX-2009 and CD166 levels suggest a role for target expression in the unmasking and/or tumor retention of CX-2009
- CD166 expression could be beneficial for patient selection
Arms A and B (CX-2009 Monotherapy)

Primary

• To evaluate the antitumor activity of CX-2009 based on objective response rate (ORR) per Central Radiology Review (CRR)

Secondary

• To evaluate the antitumor activity of CX-2009 based on ORR per Investigator assessment
• To evaluate progression-free survival (PFS), clinical benefit rate at 16 weeks (CBR16), clinical benefit rate at 24 weeks (CBR24), duration of response (DoR), and overall survival (OS)
• To characterize the safety profile of CX-2009
• To characterize the pharmacokinetics (PK) of CX-2009
• To assess the incidence of antidrug antibody (ADA) formation to CX-2009
Arm C (CX-2009 + CX-072 Combination Therapy)

Primary
• To evaluate the antitumor activity of CX-2009 in combination with CX-072, a conditionally activated IgG4 mAb prodrug to PD-L1, based on ORR per CRR

Secondary
• To evaluate the antitumor activity of CX-2009 in combination with CX-072 based on ORR per Investigator assessment
• To evaluate PFS, CBR16, CBR24, DoR, and OS
• To characterize the safety profile of CX-2009 in combination with CX-072
• To characterize the PK and assess the incidence of ADA formation with the combination of CX-2009 and CX-072
The primary endpoint will be ORR according to RECIST v1.1 based on assessment by the CRR.

- Analyses will be performed separately for each arm using the modified efficacy-evaluable population, defined as all patients who have at least 1 post-baseline tumor scan centrally assessed by the CRR.

Analysis of the Secondary Efficacy Endpoints

- The analyses specified for the primary efficacy endpoint will be repeated for Investigator-assessed ORR (as supportive measure of evidence).
- Estimates of clinical benefit rate (CBR16 and CBR24) will be determined for assessments made by both the CRR and the Investigator. DoR will also be summarized using descriptive statistics (eg, median and range) for both CRR- and Investigator-assessed responses.
- Analyses of other secondary efficacy variables will be performed for each arm in the safety-evaluable population, defined as all patients who received at least 1 dose of study drug regardless of the duration of treatment.
- PFS and OS will be summarized using Kaplan-Meier product-limit methods, including estimates of median PFS and OS, and estimates of PFS and OS survivor functions at specific timepoints (eg, 6 months) with their associated 95% CIs.
Phase 2, prospective, open-label, parallel-cohort, multicenter, 3 arm interventional study of CX-2009 monotherapy or in combination with CX-072 in patients with advanced breast cancer (NCT04596150)

<table>
<thead>
<tr>
<th>Inclusion:</th>
<th>Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>• ECOG PS 0 or 1</td>
<td><strong>Primary:</strong> ORR by Central Radiology Review</td>
</tr>
<tr>
<td>• Adequate hematologic, renal, and hepatic function</td>
<td><strong>Secondary:</strong> ORR (inv), PFS, DCR, CBR24, DoR, OS, safety, PK, ADA</td>
</tr>
<tr>
<td>• Measurable disease</td>
<td><strong>Exploratory:</strong> Biomarker correlation with outcome</td>
</tr>
<tr>
<td>• Available tumor tissue (archival or fresh biopsy) for CD166 analysis</td>
<td>• All patients are required to receive prophylactic medications against ocular adverse events</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion:</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Untreated symptomatic CNS metastases</td>
<td><strong>The study is open for enrollment</strong></td>
</tr>
<tr>
<td>• Prior malignancy within past 2 years unless considered low risk for recurrence</td>
<td></td>
</tr>
<tr>
<td>• Prior maytansinoid-containing drug conjugate treatment</td>
<td></td>
</tr>
<tr>
<td>• Arm C: history of intolerance to prior I/O treatment and/or active autoimmune disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Arm A</th>
<th><strong>Endpoints</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CX-2009 (7 mg/kg) Q3W</td>
<td><strong>Primary:</strong> ORR by Central Radiology Review</td>
</tr>
<tr>
<td>HR+/HER2- (N=40)</td>
<td><strong>Secondary:</strong> ORR (inv), PFS, DCR, CBR24, DoR, OS, safety, PK, ADA</td>
</tr>
<tr>
<td></td>
<td><strong>Exploratory:</strong> Biomarker correlation with outcome</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Arm B</th>
<th><strong>Exploratory:</strong> Biomarker correlation with outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selected for CD166 Expression</strong></td>
<td><strong>Status</strong></td>
</tr>
<tr>
<td>CX-2009 (7 mg/kg) Q3W</td>
<td><strong>The study is open for enrollment</strong></td>
</tr>
<tr>
<td>TNBC (N=40)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Arm C</th>
<th><strong>Status</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selected for CD166 + PD-L1 expression</strong></td>
<td><strong>The study is open for enrollment</strong></td>
</tr>
<tr>
<td>CX-2009 (7 mg/kg) + CX-072 (1200 mg) Q3W</td>
<td></td>
</tr>
<tr>
<td>TNBC (N=40)</td>
<td></td>
</tr>
</tbody>
</table>
Inclusion Criteria

All Patients
1. Adults ≥18 years of age with adequate organ function and measurable inoperable, locally advanced, or metastatic breast cancer

HR+/HER2- Eligibility
2. Histologically confirmed HR+/HER2- breast cancer based on the most recent analyzed biopsy defined as:
   a. ER/PgR >10% (patients with ER/PgR < 10% by IHC should be enrolled in the TNBC cohort(s) unless otherwise agreed)
   b. HER2-: IHC 0 or 1+ OR HER2/CEP17 ratio 2.0 OR average HER2 copy number <4.0 signals/cell by ISH

3. At least 2 but no more than 4 prior systemic lines of treatment
   a. At least one CDK4/6 inhibitor in any treatment setting
   b. 0-2 prior cytotoxic chemotherapy treatments in advanced setting
   c. Hormonally-based monotherapy treatments will not count toward the number of prior treatments

4. Patients with brain metastases that are ≤ 1 cm, are asymptomatic, and require treatment may be eligible after discussion with medical monitor. Patients with central nervous system lesions that are equivocal (ie, may or may not be brain metastases) as assessed by the Investigator may be enrolled without definitive local treatment
Inclusion Criteria (Cont’d)

TNBC Eligibility
1. Histologically confirmed TNBC based on the most recent analyzed biopsy
2. Tumor tissue must have CD166 expression by IHC assessed by central prescreening
3. Received at least 1 but no more than 3 prior systemic lines of treatment regimens for advanced disease
4. Received a taxane-based regimen in any setting
5. Patients with known germline BRCA 1/2 mutations must have received a platinum or PARP inhibitor
6. Tumor tissue known to be PD-L1 positive (Part C only)
Exclusion Criteria

1. History of malignancy that is active within the previous 2 years except for localized cancers that are not related to the current cancer being treated that are considered to have been cured, and present a low risk for recurrence

2. Prior maytansinoid-containing drug conjugates (ie, trastuzumab emtansine)

3. Untreated, symptomatic brain, and/or leptomeningeal metastases

4. Unresolved > Grade 1 toxicity from prior treatment (alopecia and non-acute toxicities excepted)

5. Active or chronic corneal disorders

6. Active viral hepatitis, CMV, or HIV infection

7. Significant cardiac disease

8. History of MS, or other demyelinating diseases, Eaton-Lambert syndrome, hemorrhagic or ischemic stroke within 6 months of enrollment, or alcoholic liver disease

9. Prior allogeneic solid organ, stem cell, or bone marrow transplant
Exclusion Criteria (Cont’d)

Arm C only

1. History of intolerance to prior immune CPI therapy defined as a requirement by local practice guidelines to discontinue treatment due to an immune-related adverse event

2. History of or current active autoimmune diseases, which are not a sequelae of prior immune checkpoint therapy

3. Myocarditis

4. History of intolerance to prior checkpoint inhibition

5. Immunosuppressive therapy within 14 days of C1D1 (ie, ≥10 mg daily prednisone or equivalents)

6. Progressed within 120 days of the first dose of any prior checkpoint inhibitor
REFERENCES


PRESENTING AUTHOR DISCLOSURES

Kathy D. Miller has no disclosures other than funding to support this trial.

Please contact the author at kathmill@iupui.edu for permission to reprint and/or distribute. PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.